Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros Corp has demonstrated financial resilience with a rise in other income to $2.1 million due to increased interest income from its substantial cash reserves, highlighting a strengthened balance sheet. The approval of a $100 million open-ended share repurchase program indicates management's confidence in the company's strategic trajectory and overall financial health. Notably, significant clinical trial results show a complete response in 61% of pivotal study patients and 100-day survival rates between 73% to 74%, underscoring the potential effectiveness of narsoplimab in treating serious health conditions.

Bears say

Omeros Corporation has shown a decline in research and development expenses, which indicates a reduction in investment towards advancing clinical trials, particularly the wind-down of several key studies. The discontinuation of the RIVER Phase 2a trial, the Human Abuse Potential study, and the CORAL Phase 2b trial may signal challenges in the clinical progress of its drug candidates. Such a decrease in R&D spending, coupled with potential setbacks in drug development, may adversely affect the company's growth prospects and investor confidence.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.